Clinical trials advancing stem cell science and inspiring hope. 

Join our community

Explore opportunities to participate in Hemostemix clinical trials, coming soon to individuals worldwide.

Hopeful coupl
Hemostemix is committed to advancing the science of our ACP-01 autologous stem cell therapy. Our goal is to bring new breakthroughs and therapeutic options to market to help transform the lives of patients living with vascular diseases.
Once a study has been approved to start, we can notify you that the recruitment window is open and confirm eligibility requirements.
Want to be notified when a study is open for enrollment?
 
Yes, Notify Me Learn More About Clinical Trials
Part of the study development process includes securing approval by an Institutional Review Board (IRB), which under FDA regulations, is a group that has been formally designated to review and monitor biomedical research involving human subjects.
PHASE 1 STUDY:
Treatment Of Vascular Cognitive Impairment and Dementia with Angiogenic Cell Precursors
The objective/hypothesis of this study is that the administration of the ACP-01 is safe and feasible for appropriate patient types. 
The investigators of this study propose that ACP-01 cells, derived from a hematopoietic cell lineage, have demonstrated molecular characteristics that favor the treatment of vascular cognitive impairment and dementia (VCID).
PHASE I STUDY:
Vascular Disease Basket Protocol Clinical Trial of ACP-01
This proposed basket protocol is designed to evaluate safety, feasibility, and early efficacy signals of ACP-01 in patients with any of the following:
1) Vascular dementia (earliest medically validated subtype)
2) Peripheral arterial disease (PAD)
3) Angina
4) Ischemic cardiomyopathy
5) Non-ischemic dilated cardiomyopathy
6) Congestive Heart Failure (CHF)
7) Total body ischemia

 

These studies will be investigational and the therapies under evaluation have not been approved for general use.
Submitting this form expresses interest only — it does not enroll you in a study, guarantee eligibility, or promise access to treatment. Final eligibility will be determined by the study protocol and an IRB-approved informed consent process.
About Hemostemix
Hemostemix (TSXV:HEM OTCQB:HMTXF FSE:2VFO) is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed and patented ACP-01 - an autologous (patient's own) blood-based stem cell therapy. Hemostemix has completed seven clinical studies of 318 subjects and published its results in 11 peer reviewed publications.